Ascendis Pharma A/S (ASND) Dividend Analysis
This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in company filings.
Does Ascendis Pharma A/S (ASND) pay a dividend?
Ascendis Pharma A/S (ASND) has never paid a dividend. It returns cash through buybacks instead, at roughly a 0.8% buyback yield over the last twelve months. The business does generate free cash flow of €335 million, so the absence of a dividend is a capital-allocation choice rather than an inability to pay. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Ascendis Pharma A/S (ASND) pay a dividend?+
No. Ascendis Pharma A/S (ASND) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Ascendis Pharma A/S return cash to shareholders?+
Through share buybacks rather than dividends. Over the last twelve months Ascendis Pharma A/S reduced its share count at a rate equivalent to a 0.8% buyback yield. A buyback returns value by shrinking the share count, so each remaining share owns more of the business, but unlike a dividend it pays you nothing in cash and can be stopped at any time without an announcement.
Could Ascendis Pharma A/S afford to pay a dividend?+
On the numbers, yes. Ascendis Pharma A/S generated €335 million of free cash flow, which is about €4.91 per share. If it paid out half of that, the dividend would be roughly €2.45 per share, a yield of about 1.1% at the current price. That is an illustration of capacity, not a prediction: the company has given no indication it intends to pay one.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Ascendis Pharma A/S.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.